<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113772</url>
  </required_header>
  <id_info>
    <org_study_id>Global CRO Orfadin</org_study_id>
    <nct_id>NCT04113772</nct_id>
  </id_info>
  <brief_title>Bio Equivalency 20 Mgm Orfadin and 20 Mgm of Nitisonine</brief_title>
  <acronym>Orfadin</acronym>
  <official_title>Orfadin and Nitinosine Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sutphin Drugs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sutphin Drugs</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      he purpose of this study is to determine whether Nitisinone 10 mg Tablets (Test Product are
      bioequivalent to the reference product Orfadin 10 mg
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description:

      The specific aim is to conduct a randomized, single dose, three-period crossover
      bioequivalence study in at least 18 healthy male and female subjects at a single study center
      to evaluate the in vivo performance of two formulations of Nitisinone 10 mg and the reference
      product Orfadin under fasting.

      A total of 4 healthy female and male volunteers (age 18 to 55 years old) will be entered into
      the study. Volunteers will be determined to be free of significant medical conditions as
      assessed by medical history, physical examination, and blood and urine tests. Volunteers will
      be randomly allocated to a treatment sequence, before administration of investigational
      nitinosine

      Determination of succinylacetone (SA) in blood (serum/plasma) and/or urine will be performed.
      Results from samples analyzed at the central laboratory, including determination of
      nitisinone, will be used in the evaluation of pharmacokinetics, efficacy and safety during
      the two treatment periods.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Succinylacetone level</measure>
    <time_frame>8 weeks</time_frame>
    <description>Succinylacetone level will be measured every 2 weeks for eight weeks</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4</enrollment>
  <condition>Hereditary Tyrosinemia, Type I</condition>
  <arm_group>
    <arm_group_label>Orfandin .5 mgm/kg mgm bid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two participant will receive .5 mgm/kg mgm of orfadin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitinosine .5 mgm/kg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two participant will receive .5 mgm/kg of nitinosine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitisinone</intervention_name>
    <description>Measure bio equivalency/efficacy of nitinosine and orfadin</description>
    <arm_group_label>Nitinosine .5 mgm/kg bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orfadin</intervention_name>
    <description>Orfadin</description>
    <arm_group_label>Orfandin .5 mgm/kg mgm bid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All HT-1 patients receiving Orfadin treatment are eligible for entry.

          -  Male and female patients of all ages diagnosed with HT-1.

          -  Stable lab values, including liver values &lt;2 ULN (ALP, ALT, AST, bilirubin, INR).

          -  Women of childbearing potential willing to use adequate contraception

          -  Signed informed consent/assent.

        Exclusion Criteria:

          -  Any medical condition which in the opinion of the investigator makes the patient
             unsuitable for inclusion.

          -  Enrollment in another concurrent clinical interventional study within three months
             prior to inclusion in this study.

          -  Pregnant women.

          -  Lactating women. .Known hepatitis B, hepatitis C or HIV infection.

          -  Foreseeable inability to cooperate with given instructions or study procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ajai Prakash</last_name>
    <phone>7185260310</phone>
    <email>ajaiprakashny@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lifein Multi-Specialty Hospital</name>
      <address>
        <city>Navsari</city>
        <state>Gujarat</state>
        <zip>396421</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tyrosinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitisinone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

